LCN2 and rheumatoid arthritis: In fact, we confirmed the elevated LCN2 serum levels that were recently described in RA patients versus healthy subjects [25], but we showed for the first time a dramatic decrease of LCN2 serum levels in RA patients responding to adalimumab as compared to RA patients under conventional treatment.